Good Primer on ADC and it’s potential for ADC(CDMO) player
Antibody-Drug Conjugate (ADC) manufacturing capacity is facing an unprecedented global bottleneck, pushing slot booking windows at top-tier CDMOs out to 18–24 months as of early 2026. This severe shortage is directly impacting clinical pipelines and delaying Investigational New Drug (IND) timelines across the biopharma sector.
The structural gridlock in ADC manufacturing is driven by three main compounding factors:
The Multi-Disciplinary Complexity of ADCs
Unlike standard monoclonal antibodies (mAbs) or small molecules, ADC production requires four distinct, highly specialized manufacturing steps that rarely coexist seamlessly in a single location:
Biologics Expression: Culturing the targeting monoclonal antibody (mAb).
HPAPI Synthesis: Manufacturing highly potent active pharmaceutical ingredients (HPAPIs) for the cytotoxic payload, requiring strict occupational exposure limits (OELs < 1 µg/m³).
Chemical Linker Synthesis: Creating the complex, stable chemical bridge between the antibody and payload.
Bioconjugation & Fill-Finish: Performing the precise chemical bonding under sterile, aseptic conditions.
Because very few CDMOs can execute this entire end-to-end chain internally, drug developers face highly fragmented supply chains.
A Massive Pipeline Surge vs. Specialised Bottlenecks
The market has exploded to 19 formally approved ADCs and a swelling clinical pipeline of over 600 candidates as of early 2026. The demand for high-potency containment suites, micronization (like jet milling), and advanced site-specific bioconjugation technologies has severely outstripped active market capacity.
Geopolitical Re-shoring Pressures
The capacity crunch has been heavily exacerbated by Western drug sponsors aggressively shifting programs away from historical manufacturing regions due to shifting regulatory policies and supply chain security initiatives. This has triggered a massive influx of inbound requests to US- and European-based CDMOs, leaving market leaders completely booked.
Biotech and pharma companies can no longer treat CDMO selection as a late-stage task. To safeguard commercial launches projected for 2027–2029, sponsors are now being forced to lock in commercial terms and secure capacity slots as early as Phase II trials.
A timely article in today’s Mint by Devina Mehra on the latest hot themes.
Interestingly, global diversification today is being touted at exactly the time when US trades at >26x PE (historical levels 16-20x PE) and seems extremely overstretched. This, when India has lost favour among FIIs, and trades in line with historical average valuations.
Paradoxically, just when things have started to get cheap here, the advice is to go hunt for value outside!
Or to quote Morgan Housel “History is littered with good ideas taken too far, which are indistinguishable from bad ideas.
Safal Niveshak articles always add value to my thought process. Articles may look philosophical at higher level, but if you start implementing some of those ideas, you will become more mature investor.
Personally I do not watch any News Channel (TV) for few months or rather a year now and it has helped me a lot to focus more on things which are useful to me, like Reading books, articles, walking, exercise every day. It certainly helps to avoid overdose of information as most of the information now a days does not add much value.
Totally agree. Too much talk about global investing these days. Devina is one of the few sensible voices in the industry. Her latest book “Money, Myths & Mantras” is worth reading, especially for people who have recently entered the stock market (the post-Covid generation)
Most of the time, when markets are doing well, investors may get excited and start leveraging, which can harm more than generating massive returns.
Reputation of business and also an individual could be more important than we think.
Also, we may under estimate “Circle of Competence” and start believing that, we can understand almost all businesses with little effort, only to realize at later date, that we were over confident.
Some of these are well known thoughts of Buffet, but sometimes we should read and re-read it to understand it fully.
Economist Rathin Roy asserts India’s growth will concentrate among the rich and the govt will pay for the welfare of the very poor, leaving the vast majority of the middle class in a state of income/consumption stagnation. This is the mediocre, low productivity model of India’s economy.
That is obvious, since the focus has recently shifted on Welfare models, which may keep productivity below the potential. Since there are not much opportunities for educated professionals, their wealth has started showing signs of stagnation and Experts seem to be not focusing much on opportunity / job driven environment. May be investors have to adapt to this model and adjust their framework.
The history of the Gobi desert mine that remade Mongolia’s economy — and the fight over who controls the future of the 100-year copper and gold producer.
The intense heat wave in the US is pushing the already strained grids despite new generation coming on board. More and more DC customers would rely on behind the meter power including fuel cells and gas generators. DCs switching to self generation is impacting the balance of the grids as well.
Historian and author Edward Chancellor discusses the investment boom surrounding artificial intelligence, record-breaking IPOs like that of SpaceX, and the warning signs he sees in financial markets.
(@theloggicalinvestor): “If you’ve always been confused about CFO/EBITDA, this tea stall example will make it click in under 5 minutes. Most people think profit means cash. It doesn’t. One of the simplest ways to understand a business is by looking at CFO/EBITDA. Let’s use a tea stall example for und…”